Jennifer H Han1, Paul H Edelstein, Ebbing Lautenbach. 1. Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. jennifer.han@uphs.upenn.edu
Abstract
OBJECTIVES: Recent epidemiological evidence suggests that genotypic and phenotypic characteristics that have typically distinguished community-associated methicillin-resistant Staphylococcus aureus (MRSA) and healthcare-associated MRSA strains may be evolving. The objective of this study was to examine the association between reduced vancomycin susceptibility (RVS) and staphylococcal cassette chromosome mec (SCCmec) type in MRSA bloodstream isolates. METHODS: A cohort study of patients who were hospitalized from 2007 to 2009 with S. aureus bacteraemia was conducted within a university health system. Bivariable analyses were conducted to determine the association between RVS and SCCmec type, as well as other microbiological characteristics including Panton-Valentine leucocidin, accessory gene regulator (agr) dysfunction and vancomycin heteroresistance. RESULTS: A total of 188 patients with MRSA bacteraemia were identified: 116 (61.7%) and 72 (38.3%) patients had infections due to healthcare-associated MRSA and community-associated MRSA, respectively. As defined by a vancomycin Etest MIC > 1.0 mg/L, the prevalence of RVS was 40.4%. Isolates with RVS were significantly more likely to be associated with SCCmec II compared with isolates without RVS (74.7% and 47.3%, respectively, P < 0.001), but not with Panton-Valentine leucocidin (P = 0.10), agr dysfunction (P = 0.19) or healthcare-associated infection (P = 0.36). CONCLUSIONS: The results of our study demonstrate important microbiological characteristics among MRSA isolates characterized by RVS, including a significant association between SCCmec II and elevated vancomycin MIC. It is clear that the clinical and molecular epidemiology of MRSA is evolving, and further understanding of factors determining virulence will be important for the elucidation of optimal treatment approaches for associated infections.
OBJECTIVES: Recent epidemiological evidence suggests that genotypic and phenotypic characteristics that have typically distinguished community-associated methicillin-resistant Staphylococcus aureus (MRSA) and healthcare-associated MRSA strains may be evolving. The objective of this study was to examine the association between reduced vancomycin susceptibility (RVS) and staphylococcal cassette chromosome mec (SCCmec) type in MRSA bloodstream isolates. METHODS: A cohort study of patients who were hospitalized from 2007 to 2009 with S. aureus bacteraemia was conducted within a university health system. Bivariable analyses were conducted to determine the association between RVS and SCCmec type, as well as other microbiological characteristics including Panton-Valentine leucocidin, accessory gene regulator (agr) dysfunction and vancomycin heteroresistance. RESULTS: A total of 188 patients with MRSA bacteraemia were identified: 116 (61.7%) and 72 (38.3%) patients had infections due to healthcare-associated MRSA and community-associated MRSA, respectively. As defined by a vancomycin Etest MIC > 1.0 mg/L, the prevalence of RVS was 40.4%. Isolates with RVS were significantly more likely to be associated with SCCmec II compared with isolates without RVS (74.7% and 47.3%, respectively, P < 0.001), but not with Panton-Valentine leucocidin (P = 0.10), agr dysfunction (P = 0.19) or healthcare-associated infection (P = 0.36). CONCLUSIONS: The results of our study demonstrate important microbiological characteristics among MRSA isolates characterized by RVS, including a significant association between SCCmec II and elevated vancomycin MIC. It is clear that the clinical and molecular epidemiology of MRSA is evolving, and further understanding of factors determining virulence will be important for the elucidation of optimal treatment approaches for associated infections.
Authors: Marin L Schweizer; Jon P Furuno; George Sakoulas; J Kristie Johnson; Anthony D Harris; Michelle D Shardell; Jessina C McGregor; Kerri A Thom; Eli N Perencevich Journal: Antimicrob Agents Chemother Date: 2010-12-20 Impact factor: 5.191
Authors: G Lina; Y Piémont; F Godail-Gamot; M Bes; M O Peter; V Gauduchon; F Vandenesch; J Etienne Journal: Clin Infect Dis Date: 1999-11 Impact factor: 9.079
Authors: Susan L Davis; Michael J Rybak; Muhammad Amjad; Glenn W Kaatz; Peggy S McKinnon Journal: Infect Control Hosp Epidemiol Date: 2006-09-19 Impact factor: 3.254
Authors: Kara B Mascitti; Paul H Edelstein; Neil O Fishman; Knashawn H Morales; Andrew J Baltus; Ebbing Lautenbach Journal: Infect Control Hosp Epidemiol Date: 2011-12-20 Impact factor: 3.254
Authors: Pamela A Moise; Davida S Smyth; Nadia El-Fawal; D Ashley Robinson; Patricia N Holden; Alan Forrest; George Sakoulas Journal: J Antimicrob Chemother Date: 2007-11-27 Impact factor: 5.790
Authors: Pamela A Moise; Davida S Smyth; D Ashley Robinson; Nadia El-Fawal; Carlo McCalla; George Sakoulas Journal: J Antimicrob Chemother Date: 2009-03-03 Impact factor: 5.790